Pre-Open Movers 07/03: (OMN) (SYMC) (TSLA) Higher; (UMRX) (USNA) (NUS) (more...)
- S&P hits record, Nasdaq jumps 1% as weak jobs data eases Fed tapering worries
- U.S. Added Only 266,000 Jobs in April, Well Below Estimates
- Roku (ROKU) Surges After Crushing Profit Estimates to Prompt an Upgrade to 'Buy' at Loop Capital
- Dollar slides to more than two-month low after big U.S. jobs miss
- Square (SQ) Tops Q1 EPS by 25c
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Today's Pre-Open Movers
OMNOVA Solutions Inc. (NYSE: OMN) 55% HIGHER; announced that it has entered into a definitive agreement to be acquired by Synthomer plc, a United Kingdom-based specialty chemical company, for $10.15 per share in cash. The Company also reported its second quarter fiscal 2019 earnings, which included the 10th consecutive quarter of year-over-year volume growth in its Specialty Solutions segment.
Unum Therapeutics Inc. (NASDAQ: UMRX) 26.9% LOWER; announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Phase 1 trial (ATTCK-20-2) evaluating Unums ACTR087 in combination with rituximab following lymphodepleting chemotherapy with fludarabine and cyclophosphamide in patients with relapsed/refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL). The clinical hold was initiated following the submission of a safety report by Unum to the FDA regarding one patient in the safety expansion cohort of the trial (Cohort 3) who recently experienced serious adverse events that included Grade 3 neurotoxicity and cytomegalovirus (CMV) infection, and Grade 4 respiratory distress.
Symantec (NASDAQ: SYMC) 15% HIGHER; Broadcom (NASDAQ: AVGO) is in advanced talks to buy Symantec (NASDAQ: SYMC), according to a report from Bloomberg after the market close yesterday, citing people familiar with the matter. It could reach a deal for Symantec within weeks.
USANA Health Sciences, Inc. (NYSE: USNA) 15.3% LOWER; announced preliminary second quarter results and updated its outlook for fiscal year 2019. The Company anticipates that second quarter 2019 net sales will range between $253 and $256 million, compared with $301 million in the prior-year period, and earnings per diluted share will range between $0.91 and $0.95 per diluted share, compared with $1.36 per diluted share in the prior-year period. (*Concensus sees Q2 EPS of $1.31 on revenue of $307.44)
Tesla (NASDAQ: TSLA) 7% HIGHER; In the second quarter, achieved record production of 87,048 vehicles and record deliveries of approximately 95,200 vehicles (conesnsus of 91,000). In addition, we made significant progress streamlining our global logistics and delivery operations at higher volumes, enabling cost efficiencies and improvements to our working capital position. Tesla delivered 77,550 Model 3s in the quarter, versus the consensus of 73,000.
Marker Therapeutics (NASDAQ: MRKR) 4% HIGHER; Oppenheimer initiates coverage on with a Outperform rating and a price target of $15.00.
Scorpio Bulkers Inc. (NYSE: SALT) 3% HIGHER; announced that the President of the Company, Robert Bugbee, has recently purchased an aggregate of 125,000 common shares of the Company at an average price of $4.58 per share in the open market.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 05/07: (IBIO) (BILL) (AXON) Higher; (CCIX) (APPN) (FROG) Lower (more...)
- Pre-Open Movers 05/05: (CHMA) (ATNX) (IBIO) Higher; (COCP) (ESPR) (MCFE) Lower (more...)
- After-Hours Stock Movers 05/06: (IBIO) (BILL) (AXON) Higher; (APPN) (STMP) (FROG) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesTesla, Earnings, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!